These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
607 related articles for article (PubMed ID: 27215912)
1. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912 [TBL] [Abstract][Full Text] [Related]
2. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas. Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566 [TBL] [Abstract][Full Text] [Related]
3. Early recognition of aggressive pituitary adenomas: a single-centre experience. Ceccato F; Regazzo D; Barbot M; Denaro L; Emanuelli E; Borsetto D; Rolma G; Alessio L; Gardiman MP; Lombardi G; Albiger N; D'Avella D; Scaroni C Acta Neurochir (Wien); 2018 Jan; 160(1):49-55. PubMed ID: 29170844 [TBL] [Abstract][Full Text] [Related]
4. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. Zada G; Woodmansee WW; Ramkissoon S; Amadio J; Nose V; Laws ER J Neurosurg; 2011 Feb; 114(2):336-44. PubMed ID: 20868211 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases. Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847 [TBL] [Abstract][Full Text] [Related]
6. The Importance of Long Term Follow Up After Endoscopic Pituitary Surgery: Durability of Results and Tumor Recurrence. Almeida JP; Tabasinejad R; Kalyvas A; Takami H; Mohan N; O'Halloran PJ; Sanchez MM; Velasquez C; Zadeh G; Gentili F Neurol India; 2020; 68(Supplement):S92-S100. PubMed ID: 32611898 [TBL] [Abstract][Full Text] [Related]
7. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744 [TBL] [Abstract][Full Text] [Related]
9. Endoscopic endonasal transsphenoidal removal of recurrent and regrowing pituitary adenomas: experience on a 59-patient series. Cavallo LM; Solari D; Tasiou A; Esposito F; de Angelis M; D'Enza AI; Cappabianca P World Neurosurg; 2013; 80(3-4):342-50. PubMed ID: 23046913 [TBL] [Abstract][Full Text] [Related]
10. Giant pituitary adenomas: surgical outcomes of 50 cases operated on by the endonasal endoscopic approach. Gondim JA; Almeida JP; Albuquerque LA; Gomes EF; Schops M World Neurosurg; 2014; 82(1-2):e281-90. PubMed ID: 23994073 [TBL] [Abstract][Full Text] [Related]
11. Predictors of aggressive clinical phenotype among immunohistochemically confirmed atypical adenomas. Zaidi HA; Cote DJ; Dunn IF; Laws ER J Clin Neurosci; 2016 Dec; 34():246-251. PubMed ID: 27765563 [TBL] [Abstract][Full Text] [Related]
12. Cystic versus non-cystic silent corticotrophic adenomas: clinical and histological analysis of 62 cases after microscopic transsphenoidal surgery-a retrospective, single-center study. Sumislawski P; Huckhagel T; Krajewski KL; Aberle J; Saeger W; Flitsch J; Rotermund R Sci Rep; 2023 Feb; 13(1):2468. PubMed ID: 36774403 [TBL] [Abstract][Full Text] [Related]
13. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review. de Aguiar PH; Aires R; Laws ER; Isolan GR; Logullo A; Patil C; Katznelson L Neurol Res; 2010 Dec; 32(10):1060-71. PubMed ID: 20483025 [TBL] [Abstract][Full Text] [Related]
15. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables. Matsuyama J Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139 [TBL] [Abstract][Full Text] [Related]
16. Endoscopic transsphenoidal treatment in recurrent and residual pituitary adenomas--first experience. Rudnik A; Zawadzki T; Gałuszka-Ignasiak B; Bazowski P; Duda I; Wojtacha M; Rudnik AI; Krawczyk I Minim Invasive Neurosurg; 2006 Feb; 49(1):10-4. PubMed ID: 16547875 [TBL] [Abstract][Full Text] [Related]
17. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. Meij BP; Lopes MB; Ellegala DB; Alden TD; Laws ER J Neurosurg; 2002 Feb; 96(2):195-208. PubMed ID: 11838791 [TBL] [Abstract][Full Text] [Related]
18. Fully endoscopic transsphenoidal surgery for functioning pituitary adenomas: a retrospective comparison with traditional transsphenoidal microsurgery in the same institution. D'Haens J; Van Rompaey K; Stadnik T; Haentjens P; Poppe K; Velkeniers B Surg Neurol; 2009 Oct; 72(4):336-40. PubMed ID: 19604551 [TBL] [Abstract][Full Text] [Related]
19. Endoscopic endonasal transsphenoidal approach for pituitary adenomas invading the cavernous sinus. Ceylan S; Koc K; Anik I J Neurosurg; 2010 Jan; 112(1):99-107. PubMed ID: 19480546 [TBL] [Abstract][Full Text] [Related]
20. Implications of the World Health Organization definition of atypia on surgically treated functional and non-functional pituitary adenomas. Sarkar S; Philip VJ; Cherukuri SK; Chacko AG; Chacko G Acta Neurochir (Wien); 2017 Nov; 159(11):2179-2186. PubMed ID: 28573325 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]